TransPLEX C-WTA

For Whole Transcriptome Amplification   

Commercialized in 2003 under the trade name of TransPLEX Whole Transcriptome Amplification (WTA), OmniPLEX technology has a unique approach to amplification that incorporates a denaturation first step, that enables this chemistry to work well with formalin-fixed or denatured clinical samples.

Product Sourcing

For diagnostic applications using human, animal, or plant sourced material, OmniPLEX technology is sold directly by Rubicon Genomics under the trade name TransPLEX C-WTA.  Contact Rubicon Genomics for pricing information TransPLEX C-WTA manufactured under cGMP.

Simple Fast Protocol -  Easily Automated

TransPLEX C-WTA is a 4 step protocol requiring 1 tube transfer and approximately 15 minutes of hands-on time. The reagent formulations have been designed and optimized for low level nucleic acid input (down to 1 ng for most applications) as well as high yield library synthesis output.    

High DNA Yield from Difficult and Denatured Samples

• Generates isothermal libraries with PCR amplification
• Leading choice for FFPE expression
• Amplifies 10 ng - 300 ng of RNA or formalin-fixed RNA for sequencing, microarray and PCR assays
• Excellent performance with archived FFPE samples

Amplification of Clinically Relevant Genes from FFPE or Fresh-Frozen RNA Samples

Rubicon TransPLEX C-WTA amplified FFPE RNA samples followed by microarray expression analyses demontrated a strong concordance of clinically relevant genes with fresh-frozen (FF) samples. In addition the TransPLEX C-WTA kit demonstrated greater % concordance versus NuGen Ovation® v2 Kit for FFPE RNA amplification

• 52 archived FFPE samples
• TransPLEX C-WTA was more predictive of clinical status:

• Better concordance in the most clinically relevant genes
• More accuracy
• Faster prep and less hands-on time